Bange; Johannes
Patent Applications and Registrations
Patent applications and USPTO patent grants for Bange; Johannes.The latest application filed is for "human anti-fgfr4 antibody".
- Bange; Johannes - Krailling DE
- Bange; Johannes - Planegg DE
- Bange; Johannes - Munich DE
- Bange; Johannes - Munchen DE
- Bange; Johannes - Muenchen DE
- Bange; Johannes - Neuried DE
| Patent | Date |
|---|---|
| Human anti-FGFR4 antibody Grant 10,358,498 - Abraham , et al. | 2019-07-23 |
| Human anti-FGFR4 antibody App 20170226213 - Abraham; Reimar ; et al. | 2017-08-10 |
| FGFR4 antibodies Grant 9,284,379 - Bange , et al. March 15, 2 | 2016-03-15 |
| Fgfr4 Antibodies App 20130183319 - BANGE; Johannes ; et al. | 2013-07-18 |
| FGFR4 antibodies Grant 8,394,927 - Bange , et al. March 12, 2 | 2013-03-12 |
| Method of diagnosing an RTK-hyperfunction induced disorder Grant 8,043,806 - Ullrich , et al. October 25, 2 | 2011-10-25 |
| Use Of Inhibitors For The Treatment Of Rtk-hyperfunction-induced Disorders, Particularly Cancer App 20100184686 - Ullrich; Axel ; et al. | 2010-07-22 |
| Fgfr4 Antibodies App 20100169992 - Bange; Johannes ; et al. | 2010-07-01 |
| Use of inhibitors for the treatment of RTK-hyperfunction-induced disorders, particularly cancer Grant 7,678,372 - Ullrich , et al. March 16, 2 | 2010-03-16 |
| Fgfr Agonists App 20090123462 - Bange; Johannes ; et al. | 2009-05-14 |
| Method for screening FGFR-4 agonists Grant 7,531,304 - Bange , et al. May 12, 2 | 2009-05-12 |
| Use of inhibitors for the treatment of RTK-hyperfunction-induced disorders, particularly cancer Grant 7,297,774 - Ullrich , et al. November 20, 2 | 2007-11-20 |
| Fgfr agonists App 20050153878 - Bange, Johannes ; et al. | 2005-07-14 |
| Use of inhibitors for the treatment of RTK-hyperfunction-induced disorders, particularly cancer App 20040235776 - Ullrich, Axel ; et al. | 2004-11-25 |
| Use of inhibitors for the treatment of disorders related to RTK hyperfunction, especially cancer Grant 6,770,742 - Ullrich , et al. August 3, 2 | 2004-08-03 |
| Use of inhibitors for the treatment of RTK-hyperfunction-induced disorders, particularly cancer App 20040067885 - Ullrich, Axel ; et al. | 2004-04-08 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 